Sacituzumab Govitecan in Pretreated HR+/HER2- Breast Cancer: TROPiCS-02 Trial
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
On August 26, 2022, Hope S. Rugo and colleagues from the UCSF Helen Diller Family Comprehensive Cancer Center published the primary results of the TROPiCS-02 Phase 3 clinical trial in the Journal of Clinical Oncology. The study investigated the efficacy and safety of Sacituzumab govitecan (Trodelvy) in patients with hormone receptor-positive (HR+) and HER2-negative metastatic breast cancer who had progressed after endocrine therapy and CDK4/6 inhibitors.
Study Design: TROPiCS-02 Trial
This international, multicenter, randomized trial enrolled 543 patients with heavily pretreated HR+/HER2- metastatic breast cancer (median of 3 prior therapies). Participants were randomized to receive:
- Sacituzumab govitecan Group (N=272): 10 mg/kg on days 1 and 8 of a 21-day cycle.
- Chemotherapy Group (N=271): Physician's choice of chemotherapy (Eribulin, Capecitabine, Gemcitabine, or Vinorelbine).
The primary endpoint was progression-free survival (PFS).
Key Results
The trial achieved its primary objective, demonstrating a statistically significant improvement in PFS:
- Median PFS: 5.5 months for the Sacituzumab govitecan group vs. 4.0 months for the chemotherapy group (Hazard Ratio [HR] = 0.66).
- PFS Rates:
- 6-Month PFS: 46% (Sacituzumab govitecan) vs. 30% (Chemotherapy).
- 12-Month PFS: 21% (Sacituzumab govitecan) vs. 7% (Chemotherapy).
- Overall Survival (OS): An interim analysis showed a positive trend favoring Sacituzumab govitecan, which was later confirmed as statistically significant in subsequent updates.
Safety Profile
The incidence of Grade 3 or higher adverse events was 74% in the Sacituzumab govitecan group compared to 60% in the chemotherapy group. The most common Grade 3+ toxicities for Sacituzumab govitecan were neutropenia (51% vs. 38%) and diarrhea (9% vs. 1%).
Conclusion
The TROPiCS-02 results establish Sacituzumab govitecan as an important new treatment option for patients with pretreated HR+/HER2- metastatic breast cancer who have limited choices after failing CDK4/6 inhibitors and multiple lines of endocrine therapy.
Source: Journal of Clinical Oncology - TROPiCS-02 Results
#BreastCancer #HRPositive #SacituzumabGovitecan #Trodelvy #TROPiCS02 #CancerResearch #ADC
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4